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Abstract
Background: Distinguishing endocervical adenocarcinoma (ECA) from endometrial mucinous
adenocarcinoma (EMMA) is clinically significant in view of the differences in their management and
prognosis. In this study, we used a panel of tumor markers to determine their ability to distinguish
between primary endocervical adenocarcinoma and primary endometrial mucinous
adenocarcinoma.
Methods: Immunohistochemistry using monoclonal antibodies to MUC1 (Ma695), p16, estrogen
receptor (ER), progesterone receptor (PR), and vimentin, was performed to examine 32 cases,
including 18 EMMAs and 14 ECAs. For MUC1, cases were scored based on the percentage of
staining pattern, apical, apical and cytoplasmic (A/C), or negative. For p16, cases were scored based
on the percentage of cells stained. For the rest of the antibodies, semiquantitative scoring system
was carried out.
Results: For MUC1, majority of EMMA (14 of 18 cases, 78%) showed A/C staining, whereas only
few ECA (2 of 14, 14%) were positive. The difference of MUC1 expression in the two groups of
malignancy was statistically significant (p < 0.001). Staining for p16 was positive in 10 of 14 (71%)
ECA and 4 of 18 (22%) EMMA. Estrogen receptor was positive in 3 of 14 (21%) ECA and 17 of 18
(94%) EMMA. Progesterone receptor was positive in 3 of 14 (21%) ECA and 16 of 18 (89%) EMMA.
Vimentin was positive in 1 of 14 (7%) ECA, and 9 of 18 (50%) EMA, with median and range of 0 (0–
6), and 1.5 (0–9) respectively.
Conclusion: A panel of immunohistochemical markers including MUC1, p16, ER, PR, and vimentin
is recommended, when there is morphological and clinical doubt as to the primary site of
endocervical or endometrial origin.
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Background
Distinguishing endocervical adenocarcinoma from its
endometrial counterpart is clinically significant in view of
their differences in management and prognosis. While the
treatment of endometrial carcinoma starts with surgical
staging and intraoperative assessment of the grade and
extent of tumor in the uterus, primary endocervical carci-
noma is treated by an initial radical hysterectomy and pel-
vic lymphadenectomy with or without adjuvant radiation
[1,2].
Morphologic distinction of the two gynecologic neo-
plasms can be difficult when the tumor involves the lower
uterine segment or upper endocervix, when the adenocar-
cinoma is present in both components of a fractional dila-
tion and curettage (D&C) specimen, or when there is no
in-situ component, cervical glandular intraepithelial
(CGIN), cervical intraepithelial neoplasia (CIN), or
endometrial hyperplasia [3,4]. This distinction could be
even more difficult in the mucinous subtype in which
stroma is absent, one of the features that suggests an
endometrial origin. Several studies have reported the use
of immunohistochemical analysis with monoclonal anti-
bodies to distinguish between adenocarcinomas of
endometrial and endocervical origin [3-17].
Mucins are high-molecular-weight (>200 kDa) glycopro-
teins with oligosaccharides attached to an apomucin pro-
tein backbone (core peptide) by O-glycosidic linkage
[18,19]. They are mainly synthesized by epithelial cells
and can be classified as secretory (gel-forming) and mem-
brane-associated forms. MUC1 is a transmembrane pro-
tein with a large extracellular tandem repeat domain and
can be found on the apical surface of almost all glandular
and ductal epithelial cells. There are also soluble, secreted
forms of MUC1 mucin, generated by proteolysis and/or
alternative mRNA splicing [20]. Aberrant de novo expres-
sion, overexpression, or altered glycosylation of MUC1
has been demonstrated in several human malignancies
[21]. Though the physiological role of MUC1 in the
female genital tract and its expression in endometrial
hyperplasia and carcinoma have been investigated [22-
28], the utility of MUC1 in differential diagnosis of
endocervical adenocarcinoma and endometrial mucinous
adenocarcinoma has been little explored.
The objectives of this study were to evaluate a panel of
monoclonal antibodies (MUC1, p16, ER, PR, and vimen-
tin), and assess their diagnostic value in distinguishing
between primary endocervical adenocarcinoma (ECA),
and primary endometrial mucinous adenocarcinoma
(EMMA).
Methods
Cases
Formalin-fixed, paraffin-embedded tissue blocks contain-
ing mucinous adenocarcinomas of known origin,
endocervix, and endometrium were obtained from the
surgical pathology files at Roswell Park Cancer Institute,
Buffalo, New York. Only primary endocervical and
endometrial adenocarcinomas from hysterectomy or
conization specimens with negative hysteroscopy were
included in this study. Small biopsy specimens were
excluded from the study. There were 18 endometrial
mucinous adenocarcinoma, and 14 endocervical adeno-
carcinomas of "typical" type, showing endometrioid and
mucinous features.
Immunohistochemical staining
Using the avidin-biotin complex technique, slides were
stained with the following monoclonal antibodies whose
main characteristics are summarized in Table 1.
Monoclonal antibody Ma695 (purchased from Novocas-
tra, Newcastle, UK) recognizes a sialylated carbohydrate
antigen on MUC1 mucin [29]. For MUC1 staining, Ma695
was used at a 1:100 dilution with high temperature
unmasking technique, with colonic mucosa as a positive
control. Staining for p16 used antibody E6H4 (DAKO,
Carpinteria, CA) at 1:25 dilution, with TRS retrieval and
high grade squamous dysplasia as a positive control.
Staining conditions for vimentin, estrogen receptor (ER),
and progesterone receptor (PR) are summarized in Table
1. Appropriate positive and negative controls were per-
formed.
Scoring of immunostaining
Due to the heterogeneity of Immunostaining, two blocks
from each case were stained and scored combined. The
immunoreactive score for MUC1 was the sum-total of the
percentage of each staining pattern, "purely apical", or
Table 1: Characteristics of antibodies used for evaluation.
Antibody Clone Source Antigen retrieval Dilution
MUC1 Ma695 Novocastra, Newcastle, UK High temperature 1:100
P16 E6H4 DAKO, Carpinteria, CA TRS 1:25
Vim Vim3B4 DAKO, Carpinteria, CA TRS 1:1000
ER 1D5 DAKO, Carpinteria, CA TRS/Vector 1:100
PR PgR636 DAKO, Carpinteria, CA TRS/Vector 1:200BMC Clinical Pathology 2006, 6:1 http://www.biomedcentral.com/1472-6890/6/1
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"combined apical/cytoplasmic" (A/C). For example, if
MUC1 showed "pure apical staining" in 40% of tumor
cells, "combined A/C staining" in 40% of tumor cells, and
20% of tumor cells did not stain, the scores would be 40
apical, 40 A/C, and 20 negative. These scores were statisti-
cally analyzed in a 2 × 4 table. Each staining pattern was
considered positive if it was present in >20% of the tumor.
Staining for p16 was scored depending on the percentage
of positively staining tumor cells, where p16 was consid-
ered diffusely positive when expressed in >50% of tumor
cells. A semiquantitative scoring system was applied for
ER, PR, and vimentin following the German Immunohis-
tochemical Scoring System [30] in which the final immu-
noreactive score equaled the product of the percentage of
positive cells times the average staining intensity (4). Per-
centage of positive cells was graded as follows: 0 = nega-
tive, 1 = up to 10% positive cells, 2 = 11 to 50%, 3 = 51 to
80%, 4 = >80%. Staining intensity of 0 = negative, 1 =
weakly positive, 2 = moderately positive, 3 = strongly pos-
itive. A combination of 3 or greater was considered posi-
tive for ER, PR and vimentin.
Statistical analysis
Descriptive analysis was performed to evaluate the fre-
quencies and distributions of the analytic variables. Given
the fact that most of the variables were not normally dis-
tributed, we applied Mann-Whitney U-test, a nonpara-
metric analysis technique, to examine the median
difference of each immunohistochemical biomarker
between patients with endocervical and endometrial
mucinous tumors. We also used Chi-square to test the dif-
ference of each immunohistochemical biomarker
between these two groups of patients where the biomar-
ker was classified as positive or negative for each patient.
Medians, ranges of values, and p values were reported. All
tests were 2-sided and the significance level was 0.05. All
analyses were performed using SPSS statistical software
(SPSS, Inc., Chicago, IL).
Results
MUC1 had two different expression patterns, "purely api-
cal", similar to that in normal endometrium (Fig. 1A, 1B),
and combined A/C, as seen in normal endocervical glands
(Fig. 1C, 1D). Apical staining was recorded, when distinct
membranous staining facing the lumen was present. Cyto-
plasmic staining was considered present when complete
circumferential cytoplasmic staining including the subnu-
clear area was evident. Table 2 shows the results of MUC1
staining. Apical and cytoplasmic MUC1 was seen in 14 of
18 cases (78%) of EMMA, but only 2 of 14 cases (14%) of
ECA (p < 0.001). In EMMA, the median percentage of cells
with apical and cytoplasmic MUC1 was 70% (range 0–
100), while in ECA the median was 0% (range 0–80). Api-
cal and cytoplasmic expression of MUC1 in EMMA is
exemplified in Figure 2. Purely apical MUC1, in contrast,
was more common in ECA (8 of 14 = 57% of cases) than
in EMMA (7 of 18 = 39% of cases). In ECA, the median
percentage of cells with apical MUC1 was 35% (range 0–
100), while in EMMA the median was 15% (range 0–90).
Apical staining for MUC1 in ECA is illustrated in Figure 3.
The median percentage of cells negative for MUC1 was
higher for ECA (35%, range 0–100) than for EMMA (0%,
Table 2: MUC1 expression in endocervical and endometrial adenocarcinomas
Median (range) + Cases/Total (%)1
ECA EMMA (p-value) ECA EMMA (p-value)
Apical 35 (0–100) 15 (0–90) NS 8/14 (57%) 7/18 (39%) NS
A/C 0 (0–80) 70 (0–100) <0.001 2/14 (14%) 14/18 (78%) <0.001
Negative 35 (0–100) 0 (0–90) 0.01 7/14 (50%) 2/18 (11%) 0.01
ECA, endocervical adenocarcinoma; EMMA, endometrial mucinous adenocarcinoma; A/C, apical/cytoplasmic; NS, not significant. 1 totals are >100% 
because different areas of tumors differed in staining pattern.
Normal post-menopausal endometrium (H&E, 20×) Figure 1
A, Normal post-menopausal endometrium (H&E, 20x); B, 
MUC1 immunostain in normal postmenopausal endometrium 
showing “pure apical” staining pattern (x20); C, normal 
endocervical glands (H&E, 20x); D, MUC1 immunostain in 
normal endocervical glands showing A/C staining pattern, 
(x20).
1a 1b
1c 1dBMC Clinical Pathology 2006, 6:1 http://www.biomedcentral.com/1472-6890/6/1
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range 0–90). There was no correlation between presence
of intracytoplasmic mucin and MUC1 staining pattern. In
general, while EMMA showed an apical/cytoplasmic pat-
tern, ECA was either negative or purely apical.
The results of expression of estrogen receptor, progester-
one receptor, and vimentin are shown in Table 3. Using
>3 as a cutoff, ER was positive in 3 of 14 (21%) ECA, and
17 of 18 (94%) EMMA, (p < 0.001), with median and
range of 0 (0–100), and 7.5 (2–12) respectively (p <
0.001). Progesterone receptor was positive in 3 of 14
(21%) ECA, and 16 of 18 (89%) EMMA, (p < 0.001), with
median and range of 0 (0–12), and 9 (1–12) respectively,
(p < 0.001). Endometrial adenocarcinoma had positive
staining for ER and PR far more than ECA. No statistically
significant correlation was seen between any variable of
MUC1 and ER or PR.
A cutoff >1, weak staining in 1–10% of the cells, was used
to evaluate the results of vimentin. Vimentin was positive
in 1 of 14 (7%) ECA, and 9 of 18 (50%) EMMA, (p =
0.01), with median and range of 0 (0–2), and 1.5 (0–9)
respectively, (p = 0.002). Using higher cutoff, vimentin
lost its significant value in distinguishing between ECA
and EMMA.
Table 4 shows the results of p16. In most cases, p16 stain-
ing was of both nuclear and cytoplasmic staining pattern.
Using >50% as a cutoff, p16 was positive in 10 of 14
(71%) ECA, and 4 of 18 (22%) EMMA, (p = 0.005), with
median and range of 85 (0–100), and 30 (0–100) respec-
tively (p = 0.007). In general, p16 was diffuse in ECA and
patchy in EMMA.
Discussion
The results of this study suggested that a panel of mono-
clonal antibodies directed against MUC1, p16, ER, PR,
and vimentin helped distinguish between primary ECA
and primary EMMA. While primary ECA showed diffusely
positive p16, negative or apical MUC1, and negative ER/
PR, and vimentin, primary EMMA revealed either negative
Table 3: Immunostaining results of other markers studied.
ECA EMMA p-value
ER Score 0–3 11/14 (79%) 1/18 (6%) <0.001
Score 4–12 3/14 (21%) 17/18 (94%)
Median (Range) 0 (0–12) 7.5 (2–12) <0.001
PR Score 0–3 11/14 (79%) 2/18 (11%) <0.001
Score 4–12 3/14 (21%) 16/18 (89%)
Median (Range) 0 (0–12) 9 (1–12) <0.001
Vim Score 0–3 13/14 (93%) 9/18 (50%) 0.01
Score 4–12 1/14 (7%) 9/18 (50%)
Median (Range) 0 (0–2) 1.5 (0–9) 0.002
ECA, endocervical adenocarcinoma; EMMA, endometrial mucinous adenocarcinoma; NS, not significant.
Endometrial mucinous adenocarcinoma (H&E, ×10) Figure 2
A, Endometrial mucinous adenocarcinoma (H&E, x10); B, 
MUC1 immunostain in endometrial mucinous adenocarci-
noma showing A/C staining pattern (x10); C, MUC1 immu-
nostain in endometrial mucinous adenocarcinoma showing 
A/C staining pattern (x40).
2a 2b
2c
Endocervical adenocarcinoma (H&E, ×20) Figure 3
A, Endocervical adenocarcinoma (H&E, x20); B, MUC1 
immunostain in endocervical adenocarcinoma showing apical 
staining pattern (x20).
3a 3bBMC Clinical Pathology 2006, 6:1 http://www.biomedcentral.com/1472-6890/6/1
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or focally positive p16, A/C MUC1, and positive ER/PR,
and vimentin. Due to the difficulties in distinguishing the
primary site of the tumor using H&E alone, and since pre-
operative assessing of D&C specimen is crucial in plan-
ning the patient management, this panel could be helpful
in such cases.
MUC1 (Ma695) has been studied in normal cycling
endometrium. It was consistently expressed in the normal
endometrium, following a cyclical pattern: "apical mem-
brane staining" in early and mid-proliferative
endometrium; "purely cytoplasmic staining" in late pro-
liferative endometrium; and "cytoplasmic staining with
intraluminal secretions" in secretory endometrium [22]. It
has been suggested that mucin was hormonally regulated.
It was expressed with increased abundance in the secre-
tory phase of the menstrual cycle in rabbits, revealing an
upregulation function for progesterone [28]. Staining of
MUC1 by Ma695 in postmenopausal endometrium has
not been explored. We found that MUC1 expression in
normal postmenopausal endometrium was either nega-
tive or apical. Absence of cytoplasmic expression could be
explained by below-threshold progesterone level in this
population group.
MUC1 expression was tested in endometrial carcinomas.
They were of "purely apical pattern", "purely cytoplasmic
pattern" or negative. Apical MUC1 positivity was statisti-
cally more frequent in endometrioid carcinomas com-
pared with carcinomas of non-endometrioid type [22]. In
our study, mucinous adenocarcinoma was the only sub-
type studied. This may at least in part explain why most
cases had A/C staining.
While upregulation of progesterone increased cytoplas-
mic expression of MUC1 in normal cycling endometrium
[28], negative MUC1 was significantly related to PR
expression and marginally correlated with loss of ER in
endometrial adenocarcinoma (EMA) [22]. In our study,
there was no correlation between any of MUC1 variables
and ER or PR. The small number of cases, case selection
being all of mucinous subtype, or both could explain
these results.
MUC1 expression in the non-neoplastic cervical epithe-
lium has been studied. It was unaffected by ovarian ster-
oids, confirming tissue-specific regulation of MUC1 in the
lower reproductive tract [28]. However, this notion has
not been tested in endocervical adenocarcinoma. In our
study, normal endocervical glands predominantly
expressed A/C MUC1, while the majority of ECAs were
either negative or apical. In ECA, no statistically signifi-
cant correlation between any variable of MUC1 and ER or
PR was seen. While two cases had diffuse A/C MUC1,
none had ER or PR expression. We concluded that cyto-
plasmic expression of MUC1 in ECA was unlikely affected
by hormonal expression in these neoplasms. However,
due to the limited number of cases, more studies with
larger number of cases are required to confirm this
assumption.
p16, cyclin-dependent kinase-4 inhibitor (CDK4-I), is the
product of the ink 4a gene and specifically binds to cyclin
D-cdk4/6 complexes to control the cell cycle at the G1-S
interphase. Expression of p16 has been shown in preinva-
sive, high-grade, cervical squamous lesions and in low-
grade lesions associated with high-risk human papilloma-
virus (HPV) types [31-34]. p16 overexpression in HPV-
associated lesions is probably caused by inactivation of
the retinoblastoma protein, Rb, by the E7 HPV oncopro-
tein, which acts as a p16 transcript repressor [35].
Positive p16 staining of cervical adenocarcinoma in situ
and adenocarcinoma has been noted [31-34,36]. It has
been used to distinguish between ECA and endometrial
adenocarcinoma. In these studies, p16 was diffusely posi-
tive in ECA and negative or focally positive in EMA. How-
ever, few ECAs were negative, and few EMAs were diffusely
positive [16,17].
Although McCluggage et al. [16] studied p16 expression in
endometrioid endometrial adenocarcinoma, and we stud-
Table 4: p16 expression in endocervical and endometrial adenocarcinomas.
ECA EMMA p-value
0 25
1–10 11
11–50 18
Total score (0–50) 4/14 (29%) 14/18 (78%)
51–80 33
81–100 71
Total score (51–100) 10/14 (71%) 4/18 (22%) 0.005
Median (Range) 85 (0–100) 30 (0–100) 0.007
ECA, endocervical adenocarcinoma; EMMA, endometrial mucinous adenocarcinoma.BMC Clinical Pathology 2006, 6:1 http://www.biomedcentral.com/1472-6890/6/1
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ied mucinous adenocarcinoma, diffuse p16 (>50%) was
seen in 28% and 22% of respectively. We concluded that
regardless of tumor type, p16 could be diffusely expressed
in a relatively small percentage of EMAs.
It was unclear why diffuse p16 expression was present in
EMMA. One possibility was that p16 positivity was a
result of HPV-independent mechanisms. This theory was
supported by Ansari-Lari et al. [17], who tested HPV in
situ hybridization and p16 immunostaining in 24 EMAs.
They found that while HPV was not detected in any EMA,
moderate or strong p16 staining in = 50% of tumor cells
was seen in 25% of the cases. Previous studies, however,
have identified HPV subtypes in a minority of endome-
trial adenocarcinomas [37-39]. Patchy p16 positivity may
be associated with infection by low risk HPV subtypes,
because this pattern of staining may be found in low-
grade squamous intraepithelial lesions associated with
low-risk HPV subtypes.
We found, as others did [16], that few ECAs were com-
pletely negative (n = 2), and (n = 1) respectively. The rea-
sons for these results were also unclear. It was either due
to technical failure or as a result of HPV-independent
mechanisms [16]. In another study, HPV DNA was
detected in 14 of 18 positive ECAs, and p16 was diffusely
expressed in all ECAs [17]. The authors concluded that
negative HPV DNA detection was due to technical failure
of the in situ hybridization and PCR reaction.
Reviewing the comprehensive immunoprofile of the 32
cases showed that two or more "aberrant" antibody
expressions of ER, PR, vimentin, and p16 were seen in
three ECAs (#5, 6, and 8), and one EMMA (#22) Table 5.
ER+/ PR+ immunoprofile was seen in case#5. A hysterec-
tomy specimen was examined. A primary endocervical
adenocarcinoma with no endometrial involvement was
seen. ER+/PR+ and focal p16 immunoprofile was seen in
case #6. It was a mucinous adenocarcinoma involving an
Table 5: Comprehensive list of all 33 cases showing the immunohistochemical profile of each case.
Case# Tumor site MUC1 (%) Vim ER PR P16 (%)
Apical A/C N
1E C 1 0 0 000000
2E C 001 0 0 0001 0 0
3E C 001 0 0 0001 0 0
4E C 8 0 2 0 00009 0
5E C 5 0 05 0 061 2 9 0
6 E C 7 02 01 00 1 24 1 0
7E C 3 0 07 0 0408 0
8E C 1 0 0 000060
9E C 6 0 2 0 2 0 0001 0 0
1 0 E C 001 0 0 0208 0
1 1 E C 001 0 0 0108 0
1 2 E C 001 0 0 0005 0
1 3 E C 08 0 2 0 0001 0 0
1 4 E C 4 0 6 0 02001 0 0
1 5 E M 5 0 4 0 1 0 2424 0
1 6 E M 9 0 1 0 0061 2 0
1 7 E M 1 0 9 0 04993 0
1 8 E M 7 0 1 0 2 0 0493 0
1 9 E M 01 0 0 0661 2 7 0
20 EM 50 40 10 2 12 12 0
2 1 E M 09 0 1 0 021 2 6 0
22 EM 20 80 0 0 12 1 100
2 3 E M 01 0 0 001 2 1 2 0
2 4 E M 01 0 0 09490
2 5 E M 01 0 0 091 2 62 0
26 EM 10 90 0 4 12 12 70
27 EM 10 0 90 1 12 9 30
2 8 E M 8 0 2 0 00661 0
2 9 E M 06 0 4 0 0690
3 0 E M 4 0 5 0 1 0 4694 0
31 EM 60 40 0 2 12 9 40
32 EM 20 80 0 9 12 9 40
EC : endocervix, EM, endometrial.BMC Clinical Pathology 2006, 6:1 http://www.biomedcentral.com/1472-6890/6/1
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endocervical polyp. No endometrial involvement was
present in hysteroscopy. A PR+/p16- immunoprofile was
seen in case #8. A hysterectomy specimen was examined
revealing an endocervical adenocarcinoma with no
endometrial involvement. The immnoprofile of these
cases was not consistent with either ECA or EMMA, how-
ever, cytoplasmic expression of MUC1 (0, 20, and 0
respectively) was consistent with ECA. In case #23
(EMMA), "aberrant" negative vimentin and PR expression
was seen. A hysterectomy specimen examination revealed
EMMA with no endocervical involvement. Cytoplasmic
MUC1 was present in 80% of the tumor cells, which made
the tumor more consistent with endometrial primary.
A recent study investigated whether the immunopheno-
type of mucinous carcinoma of the endometrium and
endometrioid carcinoma of the cervix was more depend-
ent on the site of origin or the differentiation of the neo-
plasm [3]. It has been found that ER (clone CC4–5)
staining was more dependent on the site of origin, being
more common in endometrial than endocervical carci-
noma, whereas vimentin positivity is more dependent on
the pattern of differentiation, being more common in
endometrioid than mucinous neoplasms. They concluded
that if a tumor exhibited strong positive staining with
vimentin and ER, it was almost certainly of endometrial
origin. In our study, mucinous type of endometrial carci-
noma was studied. This may explain the weak vimentin
positivity. Estrogen receptor and PR had a very good value
in distinguishing between primary ECA and primary
EMMA.
Conclusion
Although several groups have investigated the use of
immunohistochemical markers to distinguish between
endocervical and endometrial adenocarcinoma, the find-
ings were inconclusive and sometimes conflicting. The
reasons behind these variable results may be multifacto-
ral, including differences in clones or retrieval processes
used; difference in the selected cases for example muci-
nous versus endometrioid adenocarcinoma; or the small
size of tested specimens. In our study, mucinous subtype
of endometrial carcinoma was studied; all small biopsies
were excluded; the tumor origin was surgically verified by
examining the gross specimen; new antibody (MUC1);
and new monoclonal antibody clones for ER and PR were
used.
For practical purposes, if two or more immunostains have
to be combined, any two markers could be significantly
useful in distinguishing ECA from EMMA. However, com-
bining MUC1 with p63, ER, PR, or both ER/PR could give
the best results as illustrated in Table 6.
We found that a panel of immunohistochemical markers
consisting of ER, PR, p16, and MUC1 reliably distin-
guishes between primary ECA and primary EMMA.
Vimentin could be added to this panel when relatively
Table 6: Panel expressions of combining at least two immunostains in endocervical and endometrial adenocarcinomas.
ECA EMMA p-value
MUC1* & P16 MUC1+, P16- 0 (0%) 10 (100%) 0.001
MUC1-, P16+ 8 (100%) 0 (0%)
MUC1 & VIM MUC1+, VIM+ 1 (7.7%) 9 (69.2%) 0.004
MUC1-, VIM- 12 (92.3%) 4 (30.8%)
MUC1 & ER MUC1+, ER+ 0 (0%) 13 (100%) 0.001
MUC1-, ER- 9 (100%) 0 (0%)
MUC1 & PR MUC1+, PR+ 0 (0%) 12 (72.2%) 0.001
MUC1-, PR- 9 (100%) 0 (27.8%)
P16 & VIM P16-, VIM+ 0 (0%) 7 (77.8%) 0.002
P16+, VIM- 9 (100%) 2 (22.2%)
P16 & ER P16-, ER+ 1 (11.1%) 14 (93.3%) 0.001
P16+, ER- 8 (88.9%) 1 (6.7%)
P16 & PR P16-, PR+ 2 (18.2%) 13 (92.9%) 0.001
P16+, PR- 9 (81.8%) 1 (7.1%)
VIM & ER VIM+, ER+ 0 (0%) 9 (90%) 0.001
VIM-, ER- 10 (100%) 1 (10%)
VIM & PR VIM+, PR+ 0 (0%) 8 (88.9%) 0.001
VIM-, PR- 10 (100%) 1 (11.1%)
ER & PR ER+, PR+ 2 (16.7%) 15 (100%) 0.001
ER-, PR- 10 (83.3%) 0 (0%)
MUC1, ER & PR MUC1+, ER+, PR+ 0 (0%) 11 (100%) 0.001
MUC1-, ER-, PR- 8 (100%) 0 (0%)
ECA, endocervical adenocarcinoma; EMMA, endometrial mucinous adenocarcinoma. * Apical and cytoplasmic MUC1 expression.BMC Clinical Pathology 2006, 6:1 http://www.biomedcentral.com/1472-6890/6/1
Page 8 of 9
(page number not for citation purposes)
larger specimen is represented. Because surgical modali-
ties may differ, such a panel should be routinely used
before definitive surgery when there is morphological and
clinical doubt as to the primary site of endocervical or
endometrial adenocarcinoma origin.
Note
*Presented in part at the annual meeting of the American
Society of Clinical Pathologists, San Antonio, TX, Octo-
ber, 2004.
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